Saxenda Cost UK 2026: NHS Access, Private Prescriptions & Monthly Price Breakdown

Saxenda (liraglutide 3mg) is available through the NHS in the UK, but access is not automatic and follows specific eligibility criteria governed by NICE guidance and local commissioning decisions.

NICE criteria for Saxenda (TA664, 2020): Saxenda is recommended by NICE for adults who meet all of the following: - BMI ≥35 (or BMI ≥30 with relevant comorbidities such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea) - At least one weight-related comorbidity - Has been referred to a specialist NHS weight management service (Tier 2 or Tier 3) - Has completed at least 3 months of non-pharmacological treatment without achieving adequate weight loss

Important caveats: - NICE recommendations do not automatically mean every NHS patient meeting criteria will receive Saxenda — local ICB commissioning determines whether and how the service is funded in your area - The availability of Saxenda has been significantly impacted by the approval of Wegovy (TA875) and Mounjaro (TA924), which are now the preferred NHS weight management medications in most areas — both showing greater efficacy - Some NHS Tier 3 services that previously prescribed Saxenda have now transitioned primarily to semaglutide or tirzepatide

Prescription charge: If prescribed on the NHS, Saxenda is subject to the standard NHS prescription charge of £9.90 per item (as of 2026). Patients with a PPC (Prepayment Certificate), free prescription entitlement (e.g. those with diabetes, low income), or exempt categories pay nothing.

*NHS eligibility should be confirmed with your GP or specialist weight management team.*

For patients who do not meet NHS criteria, face long waiting lists, or prefer to access treatment more quickly, private prescription is the alternative route.

Saxenda pen specification: - Each Saxenda pen contains 18mg liraglutide in 3mL (6mg/mL) - At the maximum 3mg daily dose, each pen provides 6 days of injections - One month (30 days) at 3mg/day requires approximately 5 pens

Private Saxenda cost breakdown (approximate 2026 prices):

| Dose | Pens Required/Month | Estimated Monthly Cost | |---|---|---| | 0.6mg (starting dose) | 1 pen | £25–£40 | | 1.2mg | 2 pens | £50–£80 | | 1.8mg | 3 pens | £75–£120 | | 2.4mg | 4 pens | £100–£150 | | 3mg (maintenance) | 5 pens | £90–£180 |

The wide price range reflects variation between online providers, high street pharmacies, and private GP services. Consultation fees are additional at many providers (£50–£150 for the initial consultation).

Annual cost at maintenance dose (3mg): Approximately £1,080–£2,160/year for the medication alone, plus annual consultation/monitoring costs.

Important note: While Saxenda's monthly costs are lower than Mounjaro, its lower average weight loss efficacy (8% vs 22%) means the cost-per-kg-lost comparison may not favour Saxenda at higher doses when compared against Mounjaro's starting doses.

Saxenda is available from a range of UK private pharmacy and online prescribing services. Prices vary — and it is worth comparing before committing.

High street pharmacies: - Boots: Private prescription Saxenda available in-store at Boots pharmacy; price per pen approximately £25–£40; initial consultation required through Boots Health Service or separately with a GP - LloydsPharmacy: Available via in-store pharmacy with private prescription; similar per-pen pricing to Boots

Online prescribing services: Numerous CQC-registered online clinics and telehealth platforms offer Saxenda via video or online consultation: - Typically bundle consultation + prescription into a monthly subscription model - Monthly all-inclusive costs at 3mg: £100–£180 from reputable services - Advantages: convenience, home delivery, no GP visit required - Verify that any online provider is CQC-registered and that prescribers are GMC or GPhC registered

Independent pharmacies: Some independent pharmacies can dispense Saxenda on a private prescription written by a GP or pharmacist prescriber. Prices can be competitive — call ahead to compare.

Savings tips: - Some providers offer discount codes for new patients - 3-month supply purchases sometimes attract a discount vs monthly purchase - Prepayment arrangements can reduce per-pen cost with regular pharmacies - Consider whether switching to Wegovy or Mounjaro (with greater efficacy for a similar or moderately higher cost) represents better value for your specific situation

Supply concerns: Saxenda has occasionally experienced supply disruptions in the UK. Check stock availability before starting a course and ensure your provider can guarantee continuity of supply.

One useful feature of Saxenda for cost-conscious patients is that costs increase with dose — meaning early in treatment (at lower escalation doses), monthly costs are significantly lower than at the full 3mg maintenance dose.

The Saxenda dose escalation schedule: - Week 1: 0.6mg/day - Week 2: 1.2mg/day - Week 3: 1.8mg/day - Week 4: 2.4mg/day - Week 5 onwards: 3mg/day (maintenance)

Cost during escalation (approximate):

| Week | Daily Dose | Pens Used | Approx. Weekly Cost | |---|---|---|---| | Week 1 | 0.6mg | 0.2 pens | £5–£8 | | Week 2 | 1.2mg | 0.3 pens | £9–£15 | | Week 3 | 1.8mg | 0.5 pens | £13–£20 | | Week 4 | 2.4mg | 0.7 pens | £18–£28 | | Month 2+ | 3mg | ~1.2 pens/week | £30–£50/week |

Total first-month cost: Due to lower doses during escalation, the first month is typically less expensive than subsequent maintenance months — often £60–£100 for the full escalation month versus £90–£180 for a full 3mg maintenance month.

What the starter pack typically includes: Some providers offer a starter kit that includes pens covering the escalation period at a bundled price. Check whether your provider's pricing is structured around escalation or maintenance doses.

With the availability of Wegovy (semaglutide 2.4mg) and Mounjaro (tirzepatide) now firmly established in the UK, the question of whether Saxenda represents good value in 2026 requires honest assessment.

The case for Saxenda: - Lower monthly cost at some price points compared to Wegovy and Mounjaro - Proven track record — Saxenda has been available in the UK since 2015 and has an extensive real-world safety database - May suit certain patients — particularly those who have previously responded well to GLP-1 agonists or for whom the newer agents are contraindicated - Some NHS commissioning areas still primarily access Saxenda, making it the most accessible option while waiting for newer agents

The case against Saxenda in 2026: - Significantly lower efficacy: 8% average weight loss vs 14–15% for Wegovy and 20–22% for Mounjaro — this is a clinically meaningful difference - Daily injection burden: Weekly alternatives (Wegovy and Mounjaro) are substantially more convenient - No cardiovascular outcomes data comparable to Wegovy's SELECT trial findings - Cost-per-unit-weight-lost may not favour Saxenda when compared to Mounjaro at some dose levels

Our assessment: For most UK patients who have a choice between Saxenda, Wegovy, and Mounjaro in 2026, the clinical evidence supports Wegovy or Mounjaro as the first-line choice where affordability and access allow. Saxenda remains a valid option where it is the most accessible or affordable treatment, or where a patient has a specific clinical reason to prefer liraglutide.

*This article is for educational purposes only and does not constitute medical advice. Discuss your treatment options with a qualified UK prescribing clinician.*